CyGenica
Tuesday, February 27, 2024
Uris
Platform for Therapeutics
CyGenica, a pioneering biotech startup, revolutionises intracellular therapeutics development through their drug delivery platform, GEENIE, which promises to redefine the landscape of pharmaceutical treatments. GEENIE is not just a platform; it's a molecular tool designed to make intracellular drug delivery effortless, efficient, & significantly more targeted. GEENIE enters the target cell with a fundamentally new approach, bypasses endosomes enhancing the therapeutic efficiency of drugs.
We are currently undergoing our first commercial validation for SiRNA & ASO delivery with two esteemed pharma partners, with evaluation agreements already signed. We aim to build a robust pipeline through partnerships with four global leaders. These include a collaboration in SiRNA, addressing a Serviceable Addressable Market (SAM) of 12.6 billion USD; another in ASO, tapping into a 6 billion USD market; and a third in CRISPR, targeting a market size of 7 billion USD.
State
Cork
Country
Ireland
Website
https://www.cygenica.com
CEO/Top Company Official
Dr Nusrat J M Sanghamitra
Lead Product in Development
CYG-001 (GEENIE-small molecule/RNA/protein conjugate for oncology and genetic diseases)
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
Two
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}